research 1748 IS ANDROGENETIC ALOPECIA ASSOCIATED WITH BENIGN PROSTATIC HYPERPLASIA? ANALYSIS OF 907 PATIENTS
Hair loss is linked to higher prostate-specific antigen levels and urinary symptoms, likely due to age.
Search
for
Sort by
Research
30 / 1000+ results 
research PSA Test Sensitized by Finasteride
Finasteride improves prostate cancer detection in PSA test.
research PSA concentration change in men taking low dose finasteride and dutasteride for male androgenetic alopecia
research Association between PSA and leptin, adiponectin, HbA1c, or C-peptide among African-American and Caucasian men
Higher C-peptide levels in African-American men and higher HbA1c levels in Caucasian men are linked to lower PSA levels.
research Associations between sun sensitive pigmentary genes and serum prostate specific antigen levels
Men with less sun-sensitive skin have lower PSA levels, while men with more sun-sensitive skin have higher PSA levels.
research 1746 INCREASED SERUM C-REACTIVE PROTEIN LEVELS IMPLIES CHRONIC INFLAMMATION IS INVOLVED IN MEN WITH BENIGN PROSTATIC HYPERPLASIA AND PREDOMINANT STORAGE LOWER URINARY TRACT SYMPTOMS
Higher CRP levels suggest chronic inflammation is linked to bladder-related urinary symptoms in men with enlarged prostates.
research The Effect of 5α-Reductase Inhibition with Dutasteride and Finasteride on Semen Parameters and Serum Hormones in Healthy Men
Dutasteride and finasteride may reduce sperm count and volume but don't affect movement or shape; effects are reversible after stopping.
research Urinary Retention in Patients with BPH Treated with Finasteride or Placebo over 4 Years
Finasteride lowers risk of urinary issues and surgery by over 50% in 4 years.
research Effect of 1 mg/day finasteride on concentrations of serum prostate-specific antigen in men with androgenic alopecia: a randomised controlled trial
Taking 1 mg/day finasteride for hair loss significantly lowers PSA levels in men, which may affect prostate cancer screening.
research The Relationship Between Metformin and Serum Prostate‐Specific Antigen Levels
Metformin may lower PSA levels, possibly affecting prostate cancer development.
research 1747 PREDICTION OF BLADDER PROSTATIC OBSTRUCTION: DEVELOPMENT OF A SIMPLIFIED CLINICAL NOMOGRAM
Researchers created a simple tool to predict bladder blockage from prostate enlargement using urine flow rate and prostate volume.
research Prostate Specific Antigen Levels in Diabetic and Non-Diabetic Men from the 2001–2002 National Health and Nutrition Examination Survey
Long-term diabetes is linked to lower prostate cancer risk.
research Emerging medication for the treatment of male hypogonadism
New treatments for male hypogonadism are effective and should be personalized.
research Ottawa, Ontario, Canada, February 13–16, 2013
The document concludes that various findings in rheumatology offer insights into disease severity, treatment responses, and potential risks in medication, with some limitations due to unspecified participant numbers.
research Biochemical properties of red tilapia (Oreochromis niloticus) protein hydrolysates.
Tofacitinib effectively treated a woman's severe symptoms from a rare autoimmune condition.
research In vitro and in silico evaluation of toxicological and anti-proliferative activity in phytochemical compounds of several solvent extracts from Zaleya pentandra L
Zaleya pentandra extracts, especially acetone, may be useful for new medicines and food industry applications.
research Risk Factors for Male Lower Urinary Tract Symptoms: The Role of Metabolic Syndrome and Androgenetic Alopecia in a Latin American Population
Metabolic syndrome linked to urinary symptoms; hair loss not significant.
research Intermittent Use of Testosterone Inactivating Pharmaceuticals Using Finasteride Prolongs the Time Off Period
Using finasteride with TIP extends time off period for prostate cancer patients.
research Body Mass Index is Associated with Increased Risk of aggressive and Decreased Risk of Non-aggressive Prostate Cancer
Higher BMI is linked to a lower risk of non-aggressive prostate cancer and a higher risk of aggressive prostate cancer.
research A Case-Control Study of Physical Activity, Obesity and Energy intake and the Risk of Kidney Cancer
Being obese and eating too many calories may increase the risk of kidney cancer, but physical activity doesn't seem to affect this risk.
research Exogenous Testosterone or Testosterone with Finasteride Increases Bone Mineral Density in Older Men with Low Serum Testosterone
Testosterone therapy increases bone density in older men with low testosterone levels.
research New Progesterone Esters as 5.ALPHA.-Reductase Inhibitors.
Some new progesterone derivatives are better at blocking testosterone conversion than a common drug.
research Anti-Androgen Effects of Extracts and Compounds fromGanoderma lucidum
Ganoderma lucidum may help treat prostate cancer by blocking male hormones and slowing cancer cell growth.
research Prolongation of off-cycle interval by finasteride is not associated with survival improvement in intermittent androgen deprivation therapy in LNCaP tumor model
Finasteride doesn't improve survival in LNCaP tumor model during off-cycle of therapy.
research Comparative study of the chemical profile, cytotoxic activity, and molecular docking of Serenoa repens extract and a pharmaceutical product
Serenoa repens extract shows promise as a natural treatment for prostate cancer.
research HPLC Profiling and Insilco studies of Chochurus olitoris (Jute) Leave Fractions against Steroid 5α-Reductase 2 (SRD5α2)
Jute leaves may help reduce DHT levels, potentially aiding in conditions like hair loss and prostate issues.
research Effects of the RV3466F lotion on female telogen effluvium: Results from a 16 week, multi-centric, controlled, randomized trial
RV3466F lotion significantly reduces hair loss and improves acute telogen effluvium.
research Androgen Deprivation Therapy in Prostate Cancer: Focusing on Sexual Side Effects
Androgen Deprivation Therapy for prostate cancer often reduces sexual function but intermittent therapy may be more tolerable.
research The Long-Term Effect of Doxazosin, Finasteride, and Combination Therapy on the Clinical Progression of Benign Prostatic Hyperplasia
Combination therapy of doxazosin and finasteride safely and effectively reduces benign prostatic hyperplasia progression risk.
research The Effect of Finasteride on the Risk of Acute Urinary Retention and the Need for Surgical Treatment among Men with Benign Prostatic Hyperplasia
Finasteride reduces urinary issues and surgery need in men with enlarged prostates by over 50%.